Eton Pharmaceuticals, Inc.: updates and filings

ETONNASDAQHealthcare · Pharmaceutical Preparations

Price

$60.90

November 20, 2026Market cap $1.8B

What Ploutos Investor adds for Eton Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has risen 30% since Nov 5, 2026, when the 10-Q these figures come from was filed ($47.15 then, $61.36 on Nov 19, 2026). The figures date from before that move.10-Q
  • Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 80 daysAround Feb 8, 2027 · for Q4 2026

last Nov 5, 2026next Feb 8, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 19, 2026 latest annualNov 5, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 6, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 5, 2026Results of operations
    Form8-K
  • Nov 5, 2026Other material events
    Form8-K
  • Nov 2, 2026Other material events
    Form8-K
  • Oct 14, 2026Material agreement entered, acquisition or disposal of assets
    Form8-K
  • Sep 28, 2026Other material events
    Form8-K
  • Aug 20, 2026Filing (amendment)
    Form144/A
  • Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 13, 2026Results of operations
    Form8-K
  • Aug 5, 2026Material agreement entered, acquisition or disposal of assets
    Form8-K
  • Aug 4, 2026Officer or director change
    Form8-K
  • Jul 29, 2026Other material events
    Form8-K
  • Jul 28, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jun 9, 2026Shareholder vote
    Form8-K
  • May 19, 2026Material agreement entered, acquisition or disposal of assets
    Form8-K
  • May 14, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 14, 2026Results of operations
    Form8-K
  • May 1, 2026Other material events
    Form8-K
  • Apr 27, 2026Other material events
    Form8-K
  • Apr 24, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 16, 2026Officer or director change, Regulation FD disclosure
    Form8-K
  • Apr 15, 2026Material agreement entered, new material financial obligation
    Form8-K
  • Mar 26, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 28, 2017.

The full analysis

What do Eton Pharmaceuticals's filings show?

The filings are where every one of Eton Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.